MedTrace Logo

Serum Bio-markers in Pulmonary Hypertension

NCT04472533 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 377

Last updated 2020-07-15

No results posted yet for this study

Summary

Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by scarred blood clots in the blood vessels supplying the lungs. This in turn leads to failure of the right side of the heart. The reason why these scarred clots form is unknown. An operation to remove the scarred clots, known as pulmonary endarterectomy, is a potential cure. However, some patients have persistent obstructions within the blood vessels and heart failure even after surgery.

It is thought that abnormal levels of proteins, found in the blood stream and responsible for inflammation and the development of new blood vessels may have role in causing the disease. In this study, these proteins were measured to assess whether they provide clues as to the cause of the disease and whether they could be used for the risk stratification of patients.

Conditions

  • Pulmonary Hypertension, Primary, 4

Sponsors & Collaborators

Principal Investigators

  • Joanna Pepke-Zaba, PhD FRCP · Royal Papworth Hospital NHS Foundation Trust

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-04
Primary Completion
2017-08-31
Completion
2017-10-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04472533 on ClinicalTrials.gov